Strides Pharma Science Limited , a global pharmaceutical company, has reaffirmed its long-term revenue target for the U.S. market, signaling confidence in its growth strategy despite challenging market conditions.

Revenue Target and Margin Expectations

The company has restated its goal to achieve U.S. revenue in the range of $300-400 million by 2028. This ambitious target underscores Strides' commitment to expanding its presence in the lucrative U.S. pharmaceutical market. Additionally, Strides Pharma expects to maintain robust gross margins between 58-60%, indicating a focus on high-value products and operational efficiency.

Q1 FY2026 Performance Highlights

Strides Pharma's recent financial results for the first quarter of fiscal year 2026 demonstrate solid progress towards its long-term objectives:

U.S. Market Strategy

The company's strategy for achieving its U.S. revenue target includes:

1. Expanding its product portfolio, with one new product approval and launch in Q1 FY2026
2. Maintaining a strong market position, with 37 products ranked among the top 3 in their respective categories
3. Focusing on cost leadership and relaunching products from dormant ANDAs
4. Investing in new segments such as Control Substances Nasal Sprays and 505(b)(2) products

R&D Focus and Future Growth

Badree Komandur, MD and Group CEO of Strides Pharma, emphasized the company's commitment to enhancing its R&D efforts during the year to drive sustainable long-term growth. This focus on innovation is expected to support the company's ambitious revenue targets and maintain its competitive edge in the U.S. market.

Financial Discipline and Profitability

Strides Pharma's Q1 FY2026 results also highlight the company's focus on financial discipline and improved profitability:

The company's strong start to the fiscal year, marked by consistent growth and enhanced profitability, reflects its disciplined execution and effective cost management strategies.

As Strides Pharma continues to pursue its ambitious U.S. revenue target, investors and industry observers will be closely watching the company's progress in expanding its product portfolio, maintaining market share, and driving innovation through increased R&D investments.

Strides Pharma Science , a global pharmaceutical company, has announced its financial results for the quarter, showcasing improved operational efficiency and sales growth in key markets.

Revenue Growth and Improved Margins

The company reported a 6.2% year-over-year increase in revenue, reaching ₹1,119.70 crore. This growth was accompanied by a significant improvement in gross margin, which expanded by 300 basis points to 60.3% compared to the same period last year.

EBITDA Performance

Strides' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a growth of 10% year-over-year, amounting to ₹78.00 crore. The EBITDA margin also improved, rising by 25 basis points to 7% compared to the same quarter of the previous year.

US Market Performance

The company's US business showed resilience, with revenue growing by 7% year-over-year to $70 million in the quarter.

Exceptional Items and One-Time Gain

Strides recorded an exceptional loss of ₹8.40 crore versus an exceptional gain of ₹98.40 crore in the previous year. Additionally, the company reported a significant one-time gain of ₹3,188.00 crore.

Management Commentary

Badree Komandur, MD & Group CEO, commented on the performance: "We are pleased to report solid results, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The company will enhance its R&D efforts to drive sustainable long-term growth."

Market Response

Following the results announcement, Strides Pharma's shares traded 3.2% higher at ₹952.00.

In conclusion, Strides Pharma Science's overall operational performance and strategic initiatives position it for potential growth in the coming quarters, despite facing some challenges.